NCT02138292View on ClinicalTrials.gov

A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

February 23, 2017

Study Completion Date

February 23, 2017

Conditions
Melanoma
Interventions
DRUG

Trametinib (2mg)/Digoxin (.25mg)

"1. Trametinib (2mg) will be administered orally on a daily basis.~2. Digoxin (0.25mg) will be administered orally on a daily basis.~On a 8 week cycle, duration of treatment can last from 8 to 104 weeks."

Trial Locations (1)

75390

UT Southwestern Medical Center, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER

NCT02138292 - A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma | Biotech Hunter | Biotech Hunter